How to Build Pharma Commercial Data for AI in 2026

A lot of pharma AI projects start with the AI.
Teams pick a model, bring in an AI platform, or start developing a forecasting engine. Then the problems show up. The numbers don't match across systems. An HCP appears differently in two datasets. Historical sales data uses definitions that have changed over time.
At that point, the model gets blamed.
Usually, the real problem is the data.
Pharma companies already have plenty of commercial data. CRM systems, claims databases, payer and formulary feeds, digital engagement platforms, call-center records, field reporting tools—you name it. The hard part is bringing that information together in a way that AI can actually use.
McKinsey research found that model building accounts for only about 15% of the effort in enterprise AI projects. Most of the work goes into reconciling fragmented data and workflows before the model is ready to train.
That explains why some pharma AI pilots look promising in a demo but struggle once they have to work with real commercial data.
Why AI-ready data is different from reported data
Most commercial teams already have dashboards.
And those dashboards aren't the problem. They're useful for answering questions people already know to ask.
AI works differently.
An AI system needs consistent identifiers, clear definitions, documented lineage, and enough context to understand what each piece of data actually means. It shouldn't need a person sitting behind it explaining every field before the system can make sense of the information.
Take an HCP record as a simple example.
The CRM might use one internal ID. A syndicated data provider may use another. A digital platform could have its own identifier. If those records aren't mapped correctly, one HCP can end up looking like three different people.
The model doesn't know that. It just works with what it's given.
The scaling numbers aren't particularly encouraging either. Deloitte's 2026 life sciences outlook found that 22% of life sciences leaders reported successfully scaling AI, while only 9% said they had achieved significant returns from those investments.
So before asking AI to make commercial recommendations, the first question should be pretty basic: can the organization trust the data going into it?
A practical five-step approach to building AI-ready commercial data

1. Inventory and map every important data source Start with a list. Not just the obvious systems. Capture all the places where commercial information lives: CRM data Syndicated claims data Payer and formulary feeds Digital engagement platforms Call-center records Field reporting systems Product and territory data Sales and market-share data Then compare them. Where is the same HCP represented differently? Are territory assignments consistent? Does the product hierarchy match across systems? Is “volume” calculated the same way everywhere? These differences can look minor at first. They become a headache once you start feeding the data into a model. A good data inventory usually exposes more problems than people expect.
2. Resolve identities before building models Identity resolution isn't the most exciting part of an AI project. It may be one of the most useful. Standardize identifiers for: HCPs De-identified patient records Products Brands Territories Organizations and accounts The aim is simple: when two systems are talking about the same entity, the data architecture should know that they're talking about the same entity. This becomes especially important when CRM activity is combined with claims, access, or digital signals. If those connections are wrong, everything built on top of them becomes less reliable. Fixing identity problems early is much easier than trying to clean them up after a model has already been deployed.
3. Put governance into the data layer Governance shouldn't be a box you tick at the end of the project. Access controls, privacy requirements, lineage, and data-use rules should be built into the architecture from the start. For pharma companies, that can include requirements related to HIPAA, GDPR, and internal access policies. There is another practical benefit here. When someone questions an AI-generated recommendation, the team should be able to work backwards and see where the relevant data came from. If nobody can explain the source of a number, getting business users to trust the system becomes difficult.
4. Structure the data for actual consumption A clean data warehouse isn't automatically an AI-ready environment. The information also needs a consistent business meaning. A semantic layer can define how the organization understands important entities and metrics. A feature store can make model-ready variables available in a controlled and reusable way. That gives forecasting models, next-best-action systems, BI tools, and other applications a common foundation. Otherwise, two teams can end up calculating the same metric differently without realizing it. That's when trust in the data starts to disappear.
5. Prove the foundation with one focused use case Trying to fix every commercial process at the same time usually makes the project harder than it needs to be. Start smaller. Choose one use case where the business value is clear and the scope is manageable. Launch tracking is one option. HCP targeting can also work when the necessary data is available and properly governed. The test isn't simply whether an AI model can produce a prediction. Look at the entire process: source data → identity resolution → governance → unified data → AI or analytics → business decision If that chain works for one use case, the organization has something worth expanding. The launch, forecast, and field execution triangle Most pharma commercial AI use cases fit into three broad areas: launches, forecasting, and field execution. They have different requirements, but that doesn't mean each needs its own completely separate data environment. Launch performance Launch teams need to see early signals quickly. Call activity, formulary wins, adoption, and digital engagement can all provide clues about whether a product is tracking as expected. Waiting for a monthly report can be too slow during the early stages of a launch. A problem that appears in week four is more useful when the team can act on it in week five, rather than discovering it at the end of the quarter. Forecasting Forecasting has a different data requirement. Models often need long historical time series covering sales, claims, market share, and other commercial measures. The catch is that historical data isn't always consistent. Product definitions change. Reporting logic changes. Systems get replaced. If those changes aren't accounted for, a forecasting model can end up learning differences in the data rather than actual changes in the market. Field execution Field teams operate at a much more granular level. Rep activity, territory information, prescribing signals, and access data need to come together quickly enough to support decisions in the field. A recommendation based on information from several weeks ago might be technically accurate and still not be very useful to the person making the decision today. That's why timeliness matters just as much as accuracy here. What does AI-ready commercial data look like? There isn't one universal definition of “ready.” It depends on what the organization wants the data to support. Use case What good readiness looks like Common problem Launch tracking Weekly visibility into adoption by territory and specialty Data arrives too late to influence the first 90 days Forecasting Consistent product and volume definitions across 24+ months Historical data follows outdated system definitions Field execution Rep activity connected with prescribing and access signals CRM and claims data are reconciled too late HCP engagement analytics Unified prescribing, digital, and access signals Segmentation depends mainly on CRM data

The goal isn't to create some perfect data environment before anyone is allowed to use AI.
The data needs to be reliable enough for the decision at hand.
What pharma companies can learn from real projects
The examples in the source show the difference between reporting data and decision-oriented data.
For a pharmaceutical manufacturer, Perceptive Analytics built a production summary dashboard that provided real-time visibility into plant metrics and helped identify the reasons behind missed targets. The result wasn't just a better report; the information helped the team improve production efficiency and increase revenue.
Another example comes from work with a life sciences BI team. Trinity Life Sciences' Director of Business Intelligence described how Perceptive Analytics turned loosely defined requirements into production-quality Tableau dashboards, with the team focusing on how users would actually work with the information rather than simply following the original specification.
Then there's the specialty pharma launch example.
For a mid-size company launching an autoimmune therapy, integrated launch dashboards showed that rheumatologist adoption in the Midwest was 30% behind plan within the first six weeks. That gave the team enough time to redirect field resources and adjust messaging before the quarter closed.
That six-week window matters. The same insight arriving at the end of the quarter would have been much less useful.
Common mistakes to avoid
A few mistakes come up again and again.
Buying the AI tool first
An expensive AI platform won't fix poor identity resolution or inconsistent definitions.
If the underlying data is unreliable, the model has a bad starting point.
Treating governance as a final step
Privacy, access, lineage, and ownership need to be considered while the data architecture is being designed—not after the first model is already running.
Creating separate pipelines for every use case
Launch tracking, forecasting, and field execution need different views and levels of detail. They don't necessarily need three completely separate foundations.
Separate pipelines can also create duplicate business logic and conflicting numbers.
Leaving commercial teams out of the design
A data platform can be technically impressive and still fail if the people using it don't trust the output.
The commercial team knows which decisions matter, what the metrics mean in practice, and where a recommendation might fall apart in the real world. Their input belongs in the design process.
What enterprise examples tell us
Roche's Orchestrated Customer Engagement rollout brought sales, marketing, master data management, and promotional systems together into a unified commercial environment. The example reflects the same basic principles of connecting identities, governing data, and making it available for different commercial uses.
Eli Lilly has also emphasized the role of an AI-ready culture and operating structure in scaling AI across areas including discovery, clinical development, and patient experience.
That second point is easy to overlook.
The technology matters, but people still have to use the systems, trust the outputs, and change how decisions get made.
A simple roadmap for 2026
For pharma teams starting this work, the sequence can be fairly straightforward.
Month 1: Map the landscape
Identify the commercial systems, datasets, owners, identifiers, and major inconsistencies.
Month 2: Fix identity and definitions
Standardize HCP, product, territory, and other key identifiers. Agree on how important commercial metrics should be calculated.
Month 3: Add governance
Put access rules, privacy controls, lineage, and ownership in place.
Month 4: Build the consumption layer
Create shared business definitions and reusable structures that analytics and AI applications can work with.
Month 5: Test one use case
Choose a focused problem, such as launch tracking, and run the full workflow from source data to business decision.
After validation: Expand
Once the foundation works, extend it to forecasting, field execution, segmentation, and other AI applications.
The timeline won't be identical for every pharma company. A large enterprise with years of fragmented data will have a different starting point from a smaller organization.
The sequence, though, is hard to argue with: understand the data first, fix the foundation, then scale the AI.
FAQs
What is the first step in building pharma commercial data for AI?
Start by inventorying the commercial data sources and identifying where HCPs, products, territories, and other entities are represented differently.
Do launch tracking, forecasting, and field execution need separate data pipelines?
Not necessarily. A unified, governed foundation can support all three, with different views depending on the speed, history, and level of detail each use case requires.
How is field execution data different from forecasting data?
Field execution relies on timely rep- and territory-level information, while forecasting needs longer historical time series with consistent definitions.
Why do pharma AI pilots struggle to scale?
Fragmented and poorly governed data is a major factor. If identities, definitions, and governance aren't sorted out, even a strong model can produce results that commercial users don't trust.
How can a pharma company tell whether its commercial data is AI-ready?
Start with one focused use case. If the organization can move from source data through governance and analytics to a reliable business decision, it has a much stronger base for expanding into additional AI applications.